Jump to any asset
849 assets, updated daily
As of September 26, 2026, Johnson & Johnson (JNJ) trades at $271.22. CleaRank Financial AI rates it Hold with a fair value of $282.00, 4.0% above the current price. Wall Street's consensus target is $282.00 across 23 analysts. RSI at 38 is in neutral territory, and the price is above its 50-day average of $264.97.
Johnson & Johnson (JNJ)
Johnson & Johnson NYSE
$271.22
0.5400 (0.20%)
At close: Sep 25, 4:00 PM EDT
AI Analyst Consensus
55 / 100
Johnson & Johnson (JNJ) is currently trading at $271.22, slightly above its 50-day and 200-day moving averages ($264.97 and $240.32), indicating a neutral to slightly bullish technical posture. The company's fair value is estimated at $282.00, suggesting limited upside from current levels. Wall Street analysts maintain a 'Buy' consensus with a median price target of $282.00, reflecting an average of 23 ratings. Despite a healthy profit margin of 21.48% and a strong return on equity of 25.74%, significant insider selling totaling $193.5 million against $257.7 thousand in purchases signals a potential lack of near-term conviction from management. The company operates within the Drug Manufacturers - General industry, a sector that has seen median revenue growth of 8.1%. JNJ's own revenue growth of 6.6% trails the sector average, though its profit margin significantly outperforms the sector's median ROE of 6.9%. The stock's price-to-sales ratio of 6.67 is higher than the sector median of 3.7, suggesting a premium valuation. Key risks include the substantial insider selling and the company's revenue growth rate relative to its peers, which could temper future performance.
JNJ Price Analysis
Market Metrics
Open
$271.70
Day Range
$269.26 to $272.25
Prev Close
$270.68
Volume
4.09M
52-Week Range
$173.33 to $281.07
Market Cap
$653.61B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Valuation is broadly in line with sector peers (-1% difference), suggesting fair market pricing relative to industry standards.
JNJ Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 4 quarters, JNJ beat estimates 3 times. The stock rose 2 times the next day. Price tends to react positively to beats.
JNJ Analysis
Company's Health
4/5
12-Month Analyst Target
+3.97% Upside
Median of 23 analysts (12-month)
$282.00
AI Technical Analysis
Johnson & Johnson (JNJ) is trading above its 50-day and 200-day moving averages ($264.97 and $240.32), indicating a generally positive trend. The Relative Strength Index (RSI) at 38.47 suggests bearish momentum, implying potential for a pullback despite the upward price trend. The Moving Average Convergence Divergence (MACD) at 1.32 also points to a consolidating or slightly weakening momentum. Volume on the latest trading day was 4.09 million shares, below the average of 6.51 million, indicating subdued investor interest. Key support levels are near the 50-day SMA, while resistance may be found near recent highs. The current price action suggests a period of consolidation after recent gains, with the RSI indicating caution for further immediate upside.
ProTips
- Monitor insider transaction activity closely, as the current heavy selling trend may indicate management's concerns about near-term performance.
- Johnson & Johnson's (JNJ) RSI is in bearish territory, suggesting potential for a short-term pullback despite the stock trading above key moving averages.
- Consider the company's revenue growth rate relative to the sector; a sustained lag could impact long-term valuation.
Key Catalysts
Bearish
Heavy Insider Selling Pressure
Insiders have sold $193.5 million worth of JNJ stock against minimal purchases, indicating a potential lack of confidence in near-term prospects.
Source: Insider Trading DataNeutral
Consistent Earnings Performance
Johnson & Johnson (JNJ) has a track record of beating EPS estimates, as seen in the recent quarter ending June 2026, which provides a stable fundamental base.
Source: Earnings ReportsBullish
Positive Forward Revenue Growth Estimates
Analysts project revenue growth of 8.00% for the next quarter and 7.00% for the current year, suggesting an expected acceleration in top-line performance.
Source: Analyst EstimatesNeutral
Sector Outperformance in Profitability
JNJ's profit margin of 21.48% and ROE of 25.74% significantly exceed healthcare sector medians, demonstrating strong operational efficiency.
Source: Company FundamentalsMarket Outlook
Johnson & Johnson (JNJ) is expected to maintain its 'Hold' rating, with a base case price target of $282.00 for the next 6-12 months, reflecting limited upside from current levels. The company's strong profitability and consistent earnings, coupled with positive analyst sentiment and projected revenue growth, support its current valuation. However, the significant insider selling activity presents a notable risk that could cap upside potential. Should revenue growth accelerate beyond current projections or a major new drug approval emerge, the stock could surpass its fair value. Conversely, a failure to meet revenue growth expectations or increased regulatory scrutiny could lead to a downside scenario, potentially testing support levels around $240.32 (200-day SMA).
Key Statistics
| Market Cap | 653.61B |
|---|---|
| P/E Ratio | 31.46 |
| EPS (TTM) | 8.62 |
| Dividend Yield | 1.95% |
| 52 Week High | 281.07 |
| 52 Week Low | 173.33 |
Johnson & Johnson (JNJ) exhibits strong profitability with a net profit margin of 21.48% and a return on equity of 25.74%, significantly outperforming the sector median ROE of 6.9%. The company's debt-to-equity ratio stands at 0.58, which is in line with the sector average of 0.58, indicating a manageable debt load. Valuation metrics show JNJ trading at a P/E ratio of 31.46 and a price-to-sales ratio of 6.67. While the P/E is slightly below the sector median of 31.9, the price-to-sales ratio is notably higher than the sector median of 3.7, suggesting the market is valuing JNJ's revenue stream at a premium. The company's revenue growth of 6.6% is below the sector's median of 8.1%, which, combined with the higher P/S ratio, raises questions about the sustainability of its current valuation without stronger top-line expansion.
Earnings & Growth Analysis
Johnson & Johnson (JNJ) most recently reported earnings for the quarter ending June 2026, beating analyst estimates with an EPS of $2.90 against an expected $2.85, resulting in a 1.75% surprise and a 1.19% stock price increase. Prior quarters show a mixed performance, including a significant EPS beat in the quarter ending December 2025 (0.38 actual vs. 0.18 estimate) but a miss in the quarter ending March 2026. The company's forward revenue growth estimates for the next quarter and year are positive, with projected growth of 8.00% and 7.00% respectively, indicating an expectation of accelerating top-line performance.
Key Risks
The most significant risk for Johnson & Johnson (JNJ) is the heavy insider selling, with $193.5 million in dispositions against minimal purchases, signaling a potential lack of confidence from management in the near-term outlook. Additionally, the company's revenue growth of 6.6% lags the healthcare sector median of 8.1%, which could pressure future earnings and valuation multiples. The stock's price-to-sales ratio of 6.67, significantly above the sector median, also presents a valuation risk if revenue growth does not accelerate.
Technical Indicators
| RSI (14) | 38.47 |
|---|---|
| MACD | 1.32 |
| SMA 50 | 264.97 |
| SMA 200 | 240.32 |
RSI
Bearish
SMA Cross
Bullish
Price vs SMA
Bullish
MACD
Bullish
Golden Cross in effect with the 50-day SMA ($264.97) above the 200-day SMA ($240.32), price action is firmly bullish above key moving averages.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
-0.03
Weak correlation
Nasdaq 100 (QQQ)
-0.19
Weak correlation
Bitcoin (BTC)
-0.12
Weak correlation
Gold (XAU)
+0.10
Weak correlation
Check Custom Correlation
How does any other asset move with JNJ? One year of daily closes, Pearson correlation.
Try
JNJ Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies pick an entry style
Conservative
$268.51
Slight discount to current
Wait for small dip
Aggressive
$271.22
At current price
Enter now if confident
Risk Management
STOP LOSS
$260.45
MAX LOSS
-3.0%
Volatility-Adjusted Stop Loss
Calculated based on RSI (38.5) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$276.56
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$281.93
+5% (Conservative)
+4.0% (Aggressive)
TARGET 3
$289.99
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for JNJ is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 26, 2026.Growth of $10,000
A $10,000 investment in JNJ in September 2016 would be worth about $23,028 today, compared with about $36,004 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in JNJ today could grow to about $21,521 by 2036 in the base case, with a bull case near $46,303 and a bear case around $10,003. Projections are statistical simulations, not guarantees.
JNJ Stock Price Prediction: 2030
CleaRank's simulation projects a price near $369 for JNJ by 2030 in the base case, from $271 today (1.4x over 4 years). The downside path ends near $227. These are outcomes of a Monte Carlo simulation run on JNJ's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $230 | $293 | $373 |
| 2028 | $224 | $316 | $445 |
| 2029 | $224 | $341 | $519 |
| 2030 | $227 | $369 | $598 |
| 2031 | $231 | $398 | $684 |
| 2032 | $237 | $430 | $778 |
| 2033 | $244 | $464 | $880 |
| 2034 | $252 | $501 | $994 |
| 2035 | $261 | $541 | $1,118 |
| 2036 | $271 | $584 | $1,256 |
Method: 10,000 simulated price paths using JNJ's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
JNJ Insider Trading Analysis
Bought
$257.7K
1 Transactions
Sold
$193.5M
20 Transactions
Insiders
12
Active Traders
Avg Transaction
$9.2M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Nov 16, 2018 | GORSKY ALEX
Chief Executive Officer
|
Sell | 264.5K | $38.6M |
| Aug 13, 2026 | DUATO JOAQUIN BOIX
Chief Executive Officer
|
Sell | 123.3K | $32.2M |
| Dec 4, 2018 | FASOLO PETER M. PH.D.
Officer
|
Sell | 166.7K | $24.4M |
| Aug 22, 2025 | DUATO JOAQUIN BOIX
Chief Executive Officer
|
Sell | 125.8K | $22.5M |
| Jan 26, 2026 | DUATO JOAQUIN BOIX
Chief Executive Officer
|
Sell | 100.0K | $22.1M |
| Feb 17, 2026 | WOLK JOSEPH J
Chief Financial Officer
|
Sell | 89.7K | $21.8M |
| Feb 15, 2018 | STOFFELS PAULUS A
Officer
|
Sell | 155.3K | $20.2M |
| Feb 17, 2026 | SWANSON JAMES D
Chief Technology Officer
|
Sell | 62.1K | $15.1M |
| Jul 24, 2017 | STOFFELS PAULUS A
Officer
|
Sell | 102.7K | $13.7M |
| Nov 22, 2022 | TAUBERT JENNIFER L
Officer
|
Sell | 76.9K | $13.6M |
Page 1 of 1
Frequently Asked Questions
What is Johnson & Johnson's stock price forecast for 2030?
Based on Monte Carlo simulations, Johnson & Johnson's (JNJ) stock price is projected to be $368.52 in 2030 under a base case scenario. The downside projection is $227, and the upside projection is $598.29. These figures represent statistical outcomes, not guaranteed price targets.
Is Johnson & Johnson stock a buy right now?
Johnson & Johnson (JNJ) is currently rated a 'Hold' with a consensus score of 55. While analysts have a 'Buy' rating and a median price target of $282.00, significant insider selling and revenue growth below the sector average suggest caution.
What is Johnson & Johnson's current valuation compared to its sector?
Johnson & Johnson (JNJ) trades at a P/E ratio of 31.46, slightly below the sector median of 31.9. However, its price-to-sales ratio of 6.67 is considerably higher than the sector median of 3.7, indicating a premium valuation on its revenue.
How has Johnson & Johnson performed in recent earnings reports?
Johnson & Johnson (JNJ) recently beat expectations for the quarter ending June 2026 with EPS of $2.90 versus an estimate of $2.85. Prior quarters have shown mixed results, including a significant beat in December 2025 but a miss in March 2026.
What are the main risks facing Johnson & Johnson?
Key risks for Johnson & Johnson (JNJ) include substantial insider selling, revenue growth that trails the healthcare sector average, and a high price-to-sales ratio that may not be sustainable without stronger top-line expansion.
What is the outlook for Johnson & Johnson's revenue growth?
Analysts project Johnson & Johnson's (JNJ) revenue to grow by 5.00% in the current quarter and 8.00% in the next quarter. For the full year, revenue growth is estimated at 7.00%, and for the next year, it is projected at 7.00%.
How does Johnson & Johnson's profitability compare to its peers?
Johnson & Johnson (JNJ) demonstrates strong profitability with a net profit margin of 21.48% and a return on equity of 25.74%, significantly outperforming the healthcare sector's median ROE of 6.9%.